Laddar populära aktier...
We cut our estimates by 2-3% due to lower order intake forecast DK operations should be doing fine F...
Sales -4% vs. ABGSCe but adj. EBIT +1% in Q1 We cut sales by 5% and adj.
Redeye provides its view of Active Biotech's first quarter report of 2024.
Redeye reiterates its valuation following the Q1 2024 report.
Redeye returns following IRLAB's Q1 report and the news of a development collaboration related to IR...
2024 kan bli ett mellanår med strategiska förändringar i fokus.
Lyckegård publicerade den 10 maj år 2024 bolagets delårsrapport för det första kvartalet år 2024.
Redeye comments on the outcome of the first step of the capital raise.
Redeye updates its view on Xspray Pharma following an undramatic Q1 2024 report.
Avvecklar Mobile… Även om försäljningen av kapacitiva sensorer till mobiltelefontillverkare har börj...
Lutar åt det positiva Nettoomsättningen utvecklades något svagare än våra förväntningar i Q1(24) och...
G5 reported lower-than-expected topline in Q1, while good cost control supported solid profitability...
Gapwaves' net sales and EBITDA, excluding ACI, surpassed Redeye Research estimates (RRe).
Containers, dry bulk cargo and the number of passengers grew in Q1 y/y, but liquid bulk cargo contin...
Redeye retains its positive stance towards Hanza despite a softer Q1 report than expected, resulting...